NCT07021261View on ClinicalTrials.gov

Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

440

Participants

Timeline

Start Date

June 16, 2025

Primary Completion Date

June 16, 2030

Study Completion Date

June 16, 2032

Conditions
Breast CancerTNBC
Interventions
DRUG

Utidelone plus capecitabine

UTD2 50 mg/m²/day orally on Days 1-5, repeated every 21 days for 2 years; Capecitabine 1000 mg/m² twice daily on Days 1-14, repeated every 21 days for 8 cycles.

DRUG

Capecitabine

Capecitabine 1000 mg/m² twice daily on Days 1-14, repeated every 21 days for 8 cycles.

All Listed Sponsors
lead

Fudan University

OTHER